EASL recommendations on treatment of hepatitis C: Final update of the series - Some issues
- PMID: 33223214
- DOI: 10.1016/j.jhep.2020.10.013
EASL recommendations on treatment of hepatitis C: Final update of the series - Some issues
Keywords: Chronic hepatitis C; Direct acting antivirals; Hepatitis C virus.
Conflict of interest statement
Conflict of interest CY Dai: Consultant of Gilead, Abbvie; Speaker of Gilead, Abbvie and Merck. WL Chuang: Speaker of Gilead and Abbvie. ML Yu: Research support (grant) from Gilead and Abbott; Consultant of Gilead, Abbvie and Merck; Speaker of Gilead, Abbvie and Merck. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
Reply to: "EASL recommendations on treatment of hepatitis C: Final update of the series - some issues".J Hepatol. 2021 Feb;74(2):474-475. doi: 10.1016/j.jhep.2020.10.025. Epub 2020 Nov 20. J Hepatol. 2021. PMID: 33229012 No abstract available.
Comment on
-
EASL recommendations on treatment of hepatitis C: Final update of the series☆.J Hepatol. 2020 Nov;73(5):1170-1218. doi: 10.1016/j.jhep.2020.08.018. Epub 2020 Sep 15. J Hepatol. 2020. PMID: 32956768
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical